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Circulating blood cell counts and indices are important indicators of hematopoietic function and a number of clinical parameters, such
as blood oxygen-carrying capacity, inflammation, and hemostasis. By performing whole-exome sequence association analyses of hema-
tologic quantitative traits in 15,459 community-dwelling individuals, followed by in silico replication in up to 52,024 independent sam-
ples, we identified two previously undescribed coding variants associated with lower platelet count: a commonmissense variant in CPS1
(rs1047891,MAF¼ 0.33, discoveryþ replication p¼ 6.383 1010) and a rare synonymous variant inGFI1B (rs150813342, MAF¼ 0.009,
discovery þ replication p ¼ 1.79 3 1027). By performing CRISPR/Cas9 genome editing in hematopoietic cell lines and follow-up tar-
geted knockdown experiments in primary human hematopoietic stem and progenitor cells, we demonstrate an alternative splicing
mechanism by which the GFI1B rs150813342 variant suppresses formation of a GFI1B isoform that preferentially promotes megakaryo-
cyte differentiation and platelet production. These results demonstrate how unbiased studies of natural variation in blood cell traits can
provide insight into the regulation of human hematopoiesis.Human genetic studies have provided important insights
into hematopoiesis. Genome-wide association studies
(GWASs) performed in large, population-based samples
have identified associations of genomic regions and com-
mon genetic (usually non-coding) variants with inter-indi-
vidual differences in blood cell traits1–5, though the causal
DNA variants and their functional mechanisms often
remain elusive. Whole-exome and targeted sequencing
approaches have been used to identify rare, sometimes pri-
vate, loss (or gain)-of-function coding variants segregating
within families with hematologic traits at the extremes of
the phenotypic distribution6–12. As of yet, whole-exome
sequencing has not been applied to large population-based
cohorts well-phenotyped for hematologic traits to identify
rare, functional variation with moderate-to-large pheno-
typic effects and to provide new biologic insight.
To this end, we performed exome sequencing in 15,459
unrelated European ancestry (EU) and African American
(AA) individuals enrolled in six population-based cohort
studies (see Supplemental Note). Replication of significant1Human Genetics Center, School of Public Health, University of Texas Health S
ogy/Oncology, Boston Children’s Hospital and Department of Pediatric Oncolo
of Harvard and MIT, Cambridge, MA 02142, USA; 4Berlin-Brandenburg Scho
13353, Germany; 5The Charles Bronfman Institute for Personalized Medicin
6Department of Laboratory Medicine and Pathology, University of Minnesota,
versity Medical Center, Rotterdam 3000, the Netherlands; 8Cardiovascular Hea
Seattle, WA 98195, USA; 9Department of Neurology, School of Medicine, Bosto
of Wisconsin-Milwaukee, Milwaukee, WI 53205, USA; 11Human Genetics, Wel
netics, University of North Carolina, Chapel Hill, NC 27599, USA; 13Human G
USA; 14Department of Haematology, University of Cambridge, Cambridge CB2
icine, Department of Medicine, School of Medicine, Johns Hopkins Univer
The Amer
 2016 American Society of Human Genetics.findings was performed in up to 52,024 additional samples
via a combination of whole-exome-based or genome-based
sequencing, genotyping, and imputation (Supplemental
Note). Our a priori hypothesis was that systematic evalua-
tion of coding variation detected by exome sequence
analysis in samples unselected for blood cell traits would
identify low-frequency variants influencing hematologic
traits and could provide functional insights into hemato-
poiesis. We analyzed platelet count and 12 other blood
cell traits (Table S1). The means of the traits were as ex-
pected in a sample of unselected healthy individuals
from the population (Table S1). Association results from
single-variant and from gene-based burden and sequence
kernel association tests (SKATs) meeting our a priori signif-
icance thresholds in either EU, AA, or trans-ethnic discov-
ery meta-analyses are summarized for both previously
known and novel (whichwe define as those not reported in
the available literature) loci in Table 1 and Tables S2–S5 and
described further in the Supplemental Note. Lambda
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blood cell (RBC) traits (ACTN4, MMACHC, MYOM2, and
MRPL43). Trans-ethnic discovery meta-analyses are sum-
marized for both previously identified loci, whichwe verify
in this study, and previously unreported loci. A summary
of these findings, and driving variants, are provided in
the Supplemental Note and Table S3. None of these gene-
based SKAT or burden findings could be replicated in inde-
pendent samples. Nonetheless, a few of the individual rare
variants driving the gene-based associations in the discov-
ery sample showed suggestive evidence of association in
the replication sample (Supplemental Note and Table S3).
Among the three single-variant associations we identified
(Table 1), two coding variants were associated with lower
platelet count in our discovery sample: CPS1 rs1047891, a
common missense variant encoding p.Thr1412Asn (EU þ
AA minor-allele frequency [MAF] ¼ 0.33, EU þ AA p ¼
5.7 3 108) and GFI1B rs150813342, a rare synonymous
variant encoding p.Phe192 and located in alternatively
spliced exon 5 (EU MAF ¼ 0.009, EU p¼ 4.7 3 108; EU þ
AA MAF ¼ 0.008, EU þ AA p ¼ 2.64 3 108). One single-
nucleotide variant (SNV) result (rs9656446; EU þ AA
MAF¼ 0.03, EUþAAp¼ 1.483 107) associatedwith baso-
phils in trans-ethnic analyses was in the ATP/GTP binding
protein-like 3 (AGBL3) gene. However, the allele frequencies
in the discovery sample differed by ethnicity (EU MAF ¼
0.001 and AA MAF ¼ 0.08), and replication in samples of
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rs150813342 (EUþAAp¼ 5.713 1021) with lower platelet
counts. In the combined discovery and replication samples,
the p values for CPS1 rs1047891 and GFI1B rs150813342
were 6.3831010 and1.7931027, respectively. AManhat-
tan plot for single-variant associations with platelet count
and quantile-quantile (Q-Q) plots are shown in Figures S1–
S3. Forest plots of the discovery cohorts for the two repli-
cated findings (GFI1B rs150813342 and CPS1 rs1047891)
are provided in Figures S4 and S5, as well as regional
plots calculating linkage disequilibrium of SNVs in the
gene with respect to index SNVs (Figures S6 and S7).
AGBL3 is ametallocarboxypeptidase involved in process-
ing tubulins of the blood cell cytoskeleton. CPS1 encodes
carbamoyl-phosphate synthase 1, amitochondrial enzyme
involved in the urea cycle. TheCPS1 variant (or its LD prox-
ies) has been associated with various cardiometabolic
traits, including high-density lipoprotein (HDL) choles-
terol, homocysteine, fibrinogen, serum metabolite levels,
and kidney function.13–17GFI1B is a known transcriptional
repressor and a key regulator of platelet and red blood cell
development. There was no evidence that either CPS1
rs1047891 or GFI1B rs150813342 were significantly associ-
ated with other hematologic traits assessed in the discovery
sample (Tables S7A and S7B). Moreover, neither GFI1B
rs150813342 nor CPS1 rs1047891 was associated with
mean platelet volume, platelet aggregation, or expression
of platelet surface markers, though these analyses were
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The Amerthe median fluorescence intensity of large, platelet-marker
positive (CD41þCD61þ) events18 was detected by flow cy-
tometry in GFI1B variant carriers even after adjustment
for circulating platelet count (p < 0.0001), which could
reflect a decrease in circulating platelet aggregates or a skew-
ing of a platelet subpopulation with regards to platelet-sur-
face-marker expression or size (see Supplemental Note).
We conducted bioinformatic and functional analyses to
understand the impact of the GFI1B exon 5 synonymous
variant and the CPS1 rs1047891 variant (p.Thr1412Asn)
on gene and protein function. The CPS1 p.Thr1412Asn
amino acid substitution is predicted to be benign and toler-
ated by SIFT and PolyPhen. Moreover, according to the
GTEx Portal database, there is no evidence of an expression
quantitative trait loci (eQTL) effect for rs1047891. None-
theless, the CPS1 p.Thr1412Asn missense substitution
is located within a region critical for N-acetyl-glutamate
binding andhas been reported to result in 20%–30%higher
enzymatic activity19 and to influence vascular function.15
We initially assessed the association of rs150813342 with
GFI1B expression by using Affymetrix GeneChip Human
Exon 1.0 ST Array data on whole-blood RNA available from
881 Framingham Heart Study participants.20 There was no
evidence for association of the rs150813342 genotype with
expression of any GFI1B exon, though statistical power is
likely limited by the low frequency of the rs150813342
variant allele,whichwaspresent inonly 7of the881 individ-
uals. According to SPANR,21 rs150813342 had a predicted
effect on splicing (difference in the percentage of transcripts
with the exon spliced in [dPSI] score of 4.6). rs150813342
was predicted to disrupt a putative exon splicing enhancer
(ESE) in exon 5 that contains a consensus SRSF1 binding
motif.22 To functionally evaluate the impact of this variant
on GFI1B transcript splicing in a relevant cell type, we used
CRISPR/Cas9 genome editing to create multiple indepen-
dent isogenic K562 hematopoietic cell lines harboring the
GFI1B synonymous single-nucleotide change (Figure 1A).
These cell lines were homozygous for the variant and ex-
hibited inclusion of less than 30%of exon 5 relative to other
surrounding exons in the GFI1B mRNA (Figure 1B). Semi-
quantitative RT-PCR showed that the presence of the
synonymous variant resulted in reduced formation of the
GFI1B isoform containing exon 5 (herein referred to as
the long isoform), aswell as preferential formationof the iso-
form lacking exon 5 (herein referred to as the short isoform)
(Figures 1C and 1D). No other isoforms or intron inclusion
events were detected (Figure 1C, Figure S8).
Although GFI1B has been implicated in both RBC and
platelet production (erythropoiesis and megakaryopoiesis,
respectively),23–25 only a role for the short isoform in
erythroid cells has been suggested previously.26 We next
assessed the effect of the altered splicing of GFI1B on line-
age-specific hematopoietic differentiation. We chemically
induced differentiation of the isogenic K562 cell lines
with either hemin (to promote erythroid differentiation)
or phorbol 12-myristate 13-acetate (PMA, to promotemega-
karyocytic differentiation) (Figure 2A). Although erythroidican Journal of Human Genetics 99, 481–488, August 4, 2016 483
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Figure 1. The Variant rs150813342 Re-
sults in Reduced Formation of the Long
GFI1B Isoform and Preferential Formation
of the Short Isoform
(A) Chromatograms of the sequence sur-
rounding the altered nucleotide in GFI1B
exon 5 showing the wild-type (WT) se-
quence and sequences of isogenic hemato-
poietic K562 cell mutant clones (Mut 1,
Mut 2, and Mut 3) harboring the C>T sin-
gle-nucleotide variant (SNV) generated via
CRISPR/Cas9mediated homologous repair.
(B) qRT-PCR of GFI1B exons 4, 5, and 6
measured from isogenic control (Cont)
and mutant K562 cell clones showing
inclusion of less than 30% of GFI1B exon
5 relative to the surrounding exons in
GFI1B mRNA from mutant clones (n ¼ 3
per group). Error bars show SD.
(C) Semi-quantitative RT-PCR with GFI1B
exon 4 forward and exon 6 reverse primers
with progressively increasing cycle numbers
(26,28, and30cycles) demonstrates reduced
formation of the long GFI1B isoform and
preferential formation of the short isoform,
as well as no other intermediate isoforms
in the clones harboring the SNV.
(D) rs150813342 ispredicted todisruptapu-
tative exon splicing enhancer (ESE) in exon
5 that contains a consensus SRSF1 binding
motif. Disruption of this binding motif
results in reduced inclusion of exon 5 and
preferential formation of the short isoform.
The promotion of alternative splicing by
SRSF1 through the spliceosome complex is
indicated by an arrow to a light blue circle.
Forward (F) and reverse (R) PCR primers of
the respective exon are indicated.differentiation appeared to proceed normally, as assessed
morphologically (Figure 2B), and with expression of the
surface marker GYPA (CD235a) (Figure 2C) and ter-
minal erythroid marker genes (Figure 2D), megakaryocyte484 The American Journal of Human Genetics 99, 481–488, August 4, 2016differentiation appeared severely
impaired; the cells retained an imma-
ture blast-like morphology and failed
to upregulate the surface marker of
megakaryocyte differentiation, CD41a
(encoded by ITGA2B), and mRNAs
whose expression is characteristic of
terminal megakaryopoiesis (Figures
2B–2D, Figure S9). The megakaryocyte
genes PPBP, SELP, and PF4 were down-
regulated by an average of 8.6-, 6.7-,
and 41.1-fold, respectively, in the
isogenic clones (p ¼ 0.0001, 0.0013,
and 0.0459, respectively) versus in the
controls (Figure 2D). These results sug-
gest that the long isoform of GFI1B is
necessary for normal megakaryocyte
differentiation.
To confirm a preferential role for
this long GFI1B isoform in megakar-yocyte differentiation, we identified two independent
short hairpin RNAs (shRNAs) that specifically targeted
GFI1B exon 5, which would thereby selectively downregu-
late the long but not the short isoform. We utilized
PP
BP
SE
LP PF
4
0
1
2
3
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
AL
AS
2
RH
CE KE
L
0.0
0.5
1.0
1.5
2.0
2.5
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
PMA
72 hr
Hemin
24–96 hr
Erythroid
Differentiation
Megakaryocytic
Differentiation
Isogenic
K562
Clones
Unstained = 214
Cont = 1211
Mut = 457
CD41a
Unstained = 19
Cont = 2745
Mut = 2143
CD235a
A B Control Mutant
Baseline
Ery.
Mega.
C D
Control clones
Mutant clones
Megakaryocyte Genes
Erythroid Genes
Figure 2. Impaired Megakaryopoiesis
and Retained Erythropoiesis in K562 Cells
Harboring the rs150813342 SNV in GFI1B
Exon 5
(A) Scheme of phorbol 12-myristate 13-ac-
etate (PMA)-induced megakaryocytic dif-
ferentiation andhemin-induced erythroid
differentiation of the hematopoietic K562
cell models.
(B) RepresentativeMay-Gru¨nwald-Giemsa-
stained cytospin images of 72 hr PMA-
induced and 96hrhemin-induced isogenic
control and mutant clones showing mega-
karyocytic differentiation that appears
severely impaired, with the cells retaining
an immature blast-like morphology in the
mutant clones, whereas the erythroid dif-
ferentiation appears unaffected.
(C) Representative flow cytometry anal-
ysis of the megakaryocyte marker CD41a
and the erythroid marker CD235a further
confirmed the impairedmegakaryopoiesis
and the retained erythropoiesis as shown
by the histogram plots with the mean
fluorescence intensity (MFI) for each
marker in unstained cells, control, and
mutant clones, respectively.
(D) Gene expression analysis by qRT-PCR
of the megakaryocyte markers PPBP, SELP,
and PF4 after 72 hr of PMA-induced differ-
entiation and of the erythroid markers
ALAS2, RHCE, and KEL after 24 hr of
hemin-induced differentiation (n ¼ 3 per
group). Error bars show SD.lentiviral-mediated shRNA delivery in primary human
adult mobilized peripheral-blood hematopoietic stem
and progenitor cells (HSPCs), which are capable of differ-
entiation toward the erythroid and megakaryocyte line-
ages under appropriate culture conditions.27 We observed
a knockdown efficiency of the GFI1B long isoform by
~50% for both shRNAs, whereas the short isoform levels
increased conversely (Figures 3A and 3B), which resulted
in a 1.5- to 1.8-fold reduction in the formation of
CD41aþ megakaryocytic cells (relative to lineage-marker
negative cells) in HSPCs undergoing differentiation
(Figure 3C). In contrast, CD235aþ erythroid cells appeared
to be present in comparable percentages and numbers
(Figure 3C). Moreover, whereas numerous morphologi-The American Journal of Human Gcally mature erythroblasts could be
readily visualized in both groups,
fewer mature megakaryocytic cells
were seen with knockdown of the
long isoform than in the controls
(Figure 3D, Figure S10). Overall cell
growth appeared comparable be-
tween the knockdown and control
cells (Figure S10). These findings are
in line with our exome-sequence
association findings, in which no
significant effect was seen on circu-
lating RBC levels.GFI1B private, loss-of-function mutations (nonsense,
frameshift) in the DNA-binding fifth and sixth zinc (Zn)-
finger domains have recently been identified in families
with an autosomal-dominant form of Gray Platelet syn-
drome (GPS) or related forms of thrombocytopenia, which
are characterized by dysmegakaryopoiesis, thrombocyto-
penia, large platelets, and platelet a-granule deficiency
(MIM: 187900)28,29. The truncating GFI1B mutations re-
ported in GPS appear to have a dominant-negative effect
and inhibit transcriptional activity of the GFI1B wild-
type form. Our population study extends the allelic spec-
trum of naturally occurring GFI1B coding sequence vari-
ants associated with a lower circulating platelet count to
include a more frequent, synonymous change that altersenetics 99, 481–488, August 4, 2016 485
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Figure 3. The Long GFI1B Isoform is Critical for Megakaryopoiesis in a Human Primary Cell Model
(A) qRT-PCR of GFI1B exons 4, 5, and 6 on day 4 after infection showing the identification of two short hairpin RNAs (shRNAs) that
specifically target GFI1B exon 5 and thereby selectively downregulate the long isoform by ~50%, but not the short isoform (n ¼ 3
per group). Error bars show SD.
(B) Semi-quantitative RT-PCRwithGFI1B exon 4 forward and exon 6 reverse primers with progressively increasing cycle numbers (26, 28,
and 30 cycles) demonstrates reduced formation of the long GFI1B isoform and increased formation of the short isoform, as well as no
other intermediate isoforms in cells with targeted knockdown of GFI1B exon 5.
(C) Representative flow cytometry analysis of thrombopoietin (TPO)- and erythropoietin (EPO)-stimulated primary human hematopoi-
etic stem and progenitor cells on day 11 of differentiation with assessment of CD41aþ megakaryocytic (Meg) cells and CD235aþ
erythroid (Ery) cells.
(D) Representative May-Gru¨nwald-Giemsa-stained cytospin images of megakaryocytic cells (from day 7 of differentiation) and erythroid
cells (from day 13 of differentiation) showing immaturemegakaryocytemorphology in cells with knockdown of the longGFI1B isoform,
in comparison with the control. In contrast, maturation of erythroblasts appears unaffected.an exonic splicing enhancer, resulting in the skipping of
exon 5, containing the first and second Zn-finger domains.
Heterozygous carriers of the synonymous exon 5 variant in
GFI1B have an average platelet count that is reduced
by 25,000 to 30,000 platelets per microliter, which
would be a clinically detectable effect. We also provide
additional support for distinct roles of GFI1B long- and
short-isoforms, which are differentially expressed at
various stages of differentiation during normal hemato-
poiesis.23,30 The long GFI1B isoform is expressed in
HSPCs and lineage-committed myeloid, erythroid, and
megakaryocytic progenitors. The abnormalities in mega-
karyocyte maturation with reduced formation of the
GFI1B long isoform in the isogenic K562 cell clones con-
taining the rs150813342 variant and in primary HSPCs
with targeted suppression of the long isoform are consis-
tent with an essential role for the GFI1B long isoform
in megakaryopoiesis and platelet production. This
finding is also congruent with prior work showing that
the GFI1B short isoform is required for erythropoiesis26
and provides insight into how these different
splice variants function in distinct aspects of human
hematopoiesis.486 The American Journal of Human Genetics 99, 481–488, August 4In summary, whole-exome sequence association analysis
performed in over 15,000 samples discovered SNVs associ-
atedwith a lower platelet count in community-dwelling in-
dividuals, including a common variant in CPS1 and a rare,
synonymous variant in GFI1B. Follow-up genome editing
and targeted knockdown experiments identified a mecha-
nism by which alternative splicing associated with the
GFI1B rs150813342 variant allele suppresses formation of
a specific GFI1B long isoform that is required for line-
age-specific megakaryocyte differentiation, while being
dispensable for erythropoiesis. Functional studies coupled
with an association finding demonstrated a previously un-
appreciated splicing-based mechanism for lineage-specific
blood cell production, providing important insights into
human hematopoiesis. Genes regulated by the long GFI1B
isoform could provide additional understanding of down-
stream transcriptional events and molecular pathways
required for megakaryocyte specification and platelet pro-
duction. These findings hold promise for the development
of therapeutics for altering platelet count without adverse
effects on other blood lineages. Further characterization of
the role ofGFI1B isoforms couldhave clinical or therapeutic
implications for disorders of platelet and other blood cell, 2016
production or function, as well as for the prospect of
improving the manufacture of ex vivo cell therapies.31–33Supplemental Data
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